de Bruijn I A, Nauta J, Gerez L, Palache A M
Solvay Pharmaceuticals B.V., PO Box 900, 1380 DA Weesp, The Netherlands.
Vaccine. 2006 Nov 10;24(44-46):6629-31. doi: 10.1016/j.vaccine.2006.05.035. Epub 2006 Jun 5.
Several approaches are currently being pursued in order to improve the efficacy of influenza vaccines in elderly individuals and others who have impaired immune responses to conventional influenza vaccines. There are two influenza vaccines available for elderly subjects: Fluad (Chiron) and Invivac (Solvay Pharmaceuticals). The present clinical study was a randomized, endpoint-blind, parallel group study in elderly subjects aged 61 years and older to investigate the safety and immunogenicity of these vaccines as compared to a standard influenza vaccine Invivac (Solvay Pharmaceuticals). The three vaccines had similar immunogenicity results, whereas the tolerability profile of Invivac was better as compared to Fluad.
目前正在探索多种方法，以提高流感疫苗对老年人及其他对传统流感疫苗免疫反应受损者的效力。有两种流感疫苗可供老年受试者使用：Fluad（凯龙公司）和Invivac（苏威制药公司）。本临床研究是一项针对61岁及以上老年受试者的随机、终点盲法、平行组研究，旨在比较这两种疫苗与标准流感疫苗Invivac（苏威制药公司）相比的安全性和免疫原性。三种疫苗的免疫原性结果相似，而与Fluad相比，Invivac的耐受性更好。
